TIDMFARN
Faron Pharmaceuticals Oy
02 November 2023
Faron to present Phase 1/2 data from BEXMAB Study of
Bexmarilimab in Combination with Standard of Care in Myeloid
Malignancies at the 65th American Society of Hematology Annual
Meeting
TURKU, Finland / BOSTON, Massachusetts - November 2, 2023 -
Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company focused on tackling
cancers via novel immunotherapies, today announces that it will
present Phase 1/2 data from its ongoing BEXMAB study of
bexmarilimab in combination with standard of care (SoC) in
relapsed/refractory (r/r) acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS) patients having failed
hypomethylating agents (HMAs), at the 65th American Society of
Hematology (ASH) Annual Meeting.
The ASH Annual Meeting will take place from 9-12 December, 2023,
in San Diego, California and virtually. The poster will contain
updated clinical data from the study.
Poster presentation details:
Title: Encouraging Efficacy Observed in BEXMAB Study: A Phase
1/2 Study to Assess Safety and Efficacy of Bexmarilimab in
Combination with Standard of Care in Myeloid Malignancies
Session Date and Time : Sunday, 10 December, 2023, 6:00 PM - 8:00 PM PST
Session Title: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Location: San Diego Convention Center, Halls G-H
Lead Authors: Dr. Mika Kontro, MD, PhD, Associate Professor at
the University of Helsinki; Dr. Naval Daver, MD, Associate
Professor of Leukemia at The University of Texas MD Anderson Cancer
Center
Abstract Number: 2915
The full abstract, which contains data up to July 25, 2023, when
the abstract was submitted, is available online on the ASH Annual
Meeting & Exposition website: 65th ASH Annual Meeting &
Exposition - Hematology.org
About BEXMAB
The BEXMAB study is an open-label Phase 1/2 clinical trial
investigating bexmarilimab in combination with standard of care
(SoC) in the aggressive hematological malignancies of acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS). The primary
objective is to determine the safety and tolerability of
bexmarilimab in combination with SoC (azacitidine) treatment and to
identify the recommended Phase II dose. Directly targeting Clever-1
could limit the replication capacity of cancer cells, increase
antigen presentation, ignite an immune response, and allow current
treatments to be more effective. Clever-1 is highly expressed in
both AML and MDS and associated with therapy resistance, limited T
cell activation and poor outcomes.
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational
immunotherapy designed to overcome resistance to existing
treatments and optimize clinical outcomes, by targeting myeloid
cell function and igniting the immune system. Bexmarilimab binds to
Clever-1, an immunosuppressive receptor found on macrophages
leading to tumor growth and metastases (i.e. helps cancer evade the
immune system). By targeting the Clever-1 receptor on macrophages,
bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an
immunostimulatory (M1) one, upregulating interferon production and
priming the immune system to attack tumors and sensitizing cancer
cells to standard of care.
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global,
clinical-stage biopharmaceutical company, focused on tackling
cancers via novel immunotherapies. Its mission is to bring the
promise of immunotherapy to a broader population by uncovering
novel ways to control and harness the power of the immune system.
The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is
being investigated in Phase I/II clinical trials as a potential
therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at
www.faron.com.
Forward-Looking Statements
Certain statements in this announcement are, or may be deemed to
be, forward-looking statements. Forward looking statements are
identified by their use of terms and phrases such as "believe",
"could", "should", "expect", "hope", "seek", "envisage",
"estimate", "intend", "may", "plan", "potentially", "will" or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward-looking statements reflect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
A number of factors could cause actual results to differ
materially from the results and expectations discussed in the
forward-looking statements, many of which are beyond the control of
the Company. In addition, other factors which could cause actual
results to differ materially include the ability of the Company to
successfully license its programs within the anticipated timeframe
or at all, risks associated with vulnerability to general economic
and business conditions, competition, environmental and other
regulatory changes, actions by governmental authorities, the
availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and
other factors. Although any forward-looking statements contained in
this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward-looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward-looking statements. Subject to any continuing
obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not
undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events,
conditions or circumstances on which any such statement is
based.
For more information on BEXMAB, please visit ClinicalTrials.gov
and reference Identifier NCT05428969.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For more information please contact:
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
Media Contact
ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRANKBBKBBDDDDK
(END) Dow Jones Newswires
November 02, 2023 09:00 ET (13:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024
